RNA, U2 small nuclear 29, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-29P profile across patient tissues and cancer cell-line models. RNU2-29P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, RNU2-29P is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, RNU2-29P RNA expression shows 10,079 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CHOL, BRCA, and TGCT as cancer lineages where RNU2-29P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-29P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-29P survival associations across molecular data types. RNU2-29P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-29P RNA expression–survival associations across cancer types. High RNU2-29P expression shows unfavorable associations in CHOL, KIRC, COAD, STAD, LUAD and KIRP. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for RNU2-29P RNA expression.
This table summarizes RNU2-29P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-29P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-29P shows higher tumor expression in BRCA, LUAD and LUSC. The BRCA box plot shows higher RNU2-29P RNA expression in tumor versus normal tissue (log2 FC = +0.042, t-test p = .007).
This table shows molecular features associated with RNU2-29P in patient tissues and cancer cell lines. In patient samples, RNU2-29P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
